FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103745379> ?p ?o ?g. }

• W2103745379 endingPage "1998" @default.
• W2103745379 startingPage "1087" @default.
• W2103745379 abstract "Background: The expression of epidermal growth factor receptor (EGFR) and type I cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKAI) is associated with neoplastic transformation. By use of human renal cancer cell lines (i.e., 769-P, ACHN, A498, and SW839), we investigated the antiproliferative activity and the antitumor activity of an anti-EGFR humanized chimeric mouse monoclonal antibody, MAb C225, and a novel mixed backbone 18-mer antisense oligonucleotide, HYB 190, that targets expression of the RIα regulatory subunit of PKAI. Methods: The antiproliferative activity of MAb C225 and oligonucleotide HYB 190, alone or in combination, on different renal cancer cell lines was determined by monitoring cell growth in soft agar. In addition, the induction of apoptosis by treatment with the anti-EGFR antibody and/or antisense PKAI oligonucleotides was evaluated by flow cytometric analysis of fragmented DNA. The antitumor activity of MAb C225 and oligonucleotide HYB 190 was determined in athymic mice bearing established ACHN tumor xenografts. Cell proliferation and tumor growth data were evaluated for statistical significance using Student's t test; reported P values are two-sided. Results: MAb C225 and oligonucleotide HYB 190 inhibited colony formation in soft agar in a dose-dependent manner for all renal cancer cell lines tested. We observed a potentiation of growth inhibition and induction of apoptosis when 769-P cells and ACHN cells were treated with both agents. Combination treatment with MAb C225 and oligonucleotide HYB 190 caused regression of ACHN tumor xenografts, whereas single-agent treatment only delayed tumor growth. Conclusion: The combination of anti-EGFR MAb C225 and HYB 190 antisense PKAI oligonucleotides HYB 190 exhibited exhibited cooperative antiproliferative effects and cooperative antitumor effects on EGFR and PKAI-expressing human renal cancer cell lines. [J Natl Cancer Inst 1998;90:1087–94]" @default.
• W2103745379 created "2016-06-24" @default.
• W2103745379 creator A5012392665 @default.
• W2103745379 creator A5040413764 @default.
• W2103745379 creator A5040445172 @default.
• W2103745379 creator A5043787919 @default.
• W2103745379 creator A5050215401 @default.
• W2103745379 creator A5056034569 @default.
• W2103745379 creator A5061032529 @default.
• W2103745379 creator A5064816004 @default.
• W2103745379 creator A5069014764 @default.
• W2103745379 creator A5071099107 @default.
• W2103745379 date "1998-07-15" @default.
• W2103745379 modified "2023-09-27" @default.
• W2103745379 title "Cooperative Inhibition of Renal Cancer Growth by Anti-Epidermal Growth Factor Receptor Antibody and Protein Kinase A Antisense Oligonucleotide" @default.
• W2103745379 cites W1263601218 @default.
• W2103745379 cites W1554141309 @default.
• W2103745379 cites W1564533206 @default.
• W2103745379 cites W1570686199 @default.
• W2103745379 cites W1575835136 @default.
• W2103745379 cites W1942070062 @default.
• W2103745379 cites W1976419136 @default.
• W2103745379 cites W1979129905 @default.
• W2103745379 cites W1979895077 @default.
• W2103745379 cites W1986488244 @default.
• W2103745379 cites W1989055139 @default.
• W2103745379 cites W1990430938 @default.
• W2103745379 cites W2001453148 @default.
• W2103745379 cites W2019732628 @default.
• W2103745379 cites W2026050954 @default.
• W2103745379 cites W2030505446 @default.
• W2103745379 cites W2038882649 @default.
• W2103745379 cites W2048596513 @default.
• W2103745379 cites W2060606238 @default.
• W2103745379 cites W2061862631 @default.
• W2103745379 cites W2064047613 @default.
• W2103745379 cites W2074312161 @default.
• W2103745379 cites W2078972772 @default.
• W2103745379 cites W2079804110 @default.
• W2103745379 cites W2088658971 @default.
• W2103745379 cites W2097072725 @default.
• W2103745379 cites W2110439220 @default.
• W2103745379 cites W2169434055 @default.
• W2103745379 cites W2252336676 @default.
• W2103745379 cites W2270408419 @default.
• W2103745379 cites W2331400535 @default.
• W2103745379 cites W2768600953 @default.
• W2103745379 doi "https://doi.org/10.1093/jnci/90.14.1087" @default.
• W2103745379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9672257" @default.
• W2103745379 hasPublicationYear "1998" @default.
• W2103745379 type Work @default.
• W2103745379 sameAs 2103745379 @default.
• W2103745379 citedByCount "75" @default.
• W2103745379 countsByYear W21037453792012 @default.
• W2103745379 countsByYear W21037453792014 @default.
• W2103745379 countsByYear W21037453792015 @default.
• W2103745379 countsByYear W21037453792016 @default.
• W2103745379 countsByYear W21037453792018 @default.
• W2103745379 countsByYear W21037453792021 @default.
• W2103745379 countsByYear W21037453792022 @default.
• W2103745379 crossrefType "journal-article" @default.
• W2103745379 hasAuthorship W2103745379A5012392665 @default.
• W2103745379 hasAuthorship W2103745379A5040413764 @default.
• W2103745379 hasAuthorship W2103745379A5040445172 @default.
• W2103745379 hasAuthorship W2103745379A5043787919 @default.
• W2103745379 hasAuthorship W2103745379A5050215401 @default.
• W2103745379 hasAuthorship W2103745379A5056034569 @default.
• W2103745379 hasAuthorship W2103745379A5061032529 @default.
• W2103745379 hasAuthorship W2103745379A5064816004 @default.
• W2103745379 hasAuthorship W2103745379A5069014764 @default.
• W2103745379 hasAuthorship W2103745379A5071099107 @default.
• W2103745379 hasBestOaLocation W21037453791 @default.
• W2103745379 hasConcept C121608353 @default.
• W2103745379 hasConcept C129312508 @default.
• W2103745379 hasConcept C153911025 @default.
• W2103745379 hasConcept C159654299 @default.
• W2103745379 hasConcept C190283241 @default.
• W2103745379 hasConcept C203014093 @default.
• W2103745379 hasConcept C2776362946 @default.
• W2103745379 hasConcept C2779707156 @default.
• W2103745379 hasConcept C502942594 @default.
• W2103745379 hasConcept C542903549 @default.
• W2103745379 hasConcept C54355233 @default.
• W2103745379 hasConcept C552990157 @default.
• W2103745379 hasConcept C55493867 @default.
• W2103745379 hasConcept C62112901 @default.
• W2103745379 hasConcept C81885089 @default.
• W2103745379 hasConcept C86803240 @default.
• W2103745379 hasConcept C96232424 @default.
• W2103745379 hasConceptScore W2103745379C121608353 @default.
• W2103745379 hasConceptScore W2103745379C129312508 @default.
• W2103745379 hasConceptScore W2103745379C153911025 @default.
• W2103745379 hasConceptScore W2103745379C159654299 @default.
• W2103745379 hasConceptScore W2103745379C190283241 @default.
• W2103745379 hasConceptScore W2103745379C203014093 @default.
• W2103745379 hasConceptScore W2103745379C2776362946 @default.
• W2103745379 hasConceptScore W2103745379C2779707156 @default.
• W2103745379 hasConceptScore W2103745379C502942594 @default.

• next